229 related articles for article (PubMed ID: 35762447)
1. Safety and efficacy of therapies for chylomicronemia.
Shamsudeen I; Hegele RA
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):395-405. PubMed ID: 35762447
[TBL] [Abstract][Full Text] [Related]
2. Etiology and emerging treatments for familial chylomicronemia syndrome.
Spagnuolo CM; Hegele RA
Expert Rev Endocrinol Metab; 2024 Jul; 19(4):299-306. PubMed ID: 38866702
[TBL] [Abstract][Full Text] [Related]
3. Updates in Drug Treatment of Severe Hypertriglyceridemia.
Gouni-Berthold I; Schwarz J; Berthold HK
Curr Atheroscler Rep; 2023 Oct; 25(10):701-709. PubMed ID: 37642858
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
Chaudhry R; Viljoen A; Wierzbicki AS
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
[TBL] [Abstract][Full Text] [Related]
6. Volanesorsen for treatment of familial chylomicronemia syndrome.
Lazarte J; Hegele RA
Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):685-693. PubMed ID: 34261380
[TBL] [Abstract][Full Text] [Related]
7. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Witztum JL; Gaudet D; Freedman SD; Alexander VJ; Digenio A; Williams KR; Yang Q; Hughes SG; Geary RS; Arca M; Stroes ESG; Bergeron J; Soran H; Civeira F; Hemphill L; Tsimikas S; Blom DJ; O'Dea L; Bruckert E
N Engl J Med; 2019 Aug; 381(6):531-542. PubMed ID: 31390500
[TBL] [Abstract][Full Text] [Related]
8. Volanesorsen for treatment of patients with familial chylomicronemia syndrome.
Warden BA; Duell PB
Drugs Today (Barc); 2018 Dec; 54(12):721-735. PubMed ID: 30596391
[TBL] [Abstract][Full Text] [Related]
9. Volanesorsen: First Global Approval.
Paik J; Duggan S
Drugs; 2019 Aug; 79(12):1349-1354. PubMed ID: 31301033
[TBL] [Abstract][Full Text] [Related]
10. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment.
Gallo A; Béliard S; D'Erasmo L; Bruckert E
Curr Atheroscler Rep; 2020 Aug; 22(11):63. PubMed ID: 32852651
[TBL] [Abstract][Full Text] [Related]
11. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
[TBL] [Abstract][Full Text] [Related]
12. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
Esan O; Wierzbicki AS
Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
[TBL] [Abstract][Full Text] [Related]
13. Severe hypertriglyceridemia: Existing and emerging therapies.
Malick WA; Do R; Rosenson RS
Pharmacol Ther; 2023 Nov; 251():108544. PubMed ID: 37848164
[TBL] [Abstract][Full Text] [Related]
14. Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia.
Nurmohamed NS; Dallinga-Thie GM; Stroes ESG
Expert Rev Cardiovasc Ther; 2020 Jun; 18(6):355-361. PubMed ID: 32511037
[TBL] [Abstract][Full Text] [Related]
15. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
Stroes ESG; Alexander VJ; Karwatowska-Prokopczuk E; Hegele RA; Arca M; Ballantyne CM; Soran H; Prohaska TA; Xia S; Ginsberg HN; Witztum JL; Tsimikas S;
N Engl J Med; 2024 May; 390(19):1781-1792. PubMed ID: 38587247
[TBL] [Abstract][Full Text] [Related]
16. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.
Witztum JL; Gaudet D; Arca M; Jones A; Soran H; Gouni-Berthold I; Stroes ESG; Alexander VJ; Jones R; Watts L; Xia S; Tsimikas S
J Clin Lipidol; 2023; 17(3):342-355. PubMed ID: 37100699
[TBL] [Abstract][Full Text] [Related]
17. Advances in the care of lipodystrophies.
Shamsudeen I; Hegele RA
Curr Opin Endocrinol Diabetes Obes; 2022 Apr; 29(2):152-160. PubMed ID: 34839327
[TBL] [Abstract][Full Text] [Related]
18. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
Falko JM
Endocr Pract; 2018 Aug; 24(8):756-763. PubMed ID: 30183397
[TBL] [Abstract][Full Text] [Related]
19. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study.
Arca M; Hsieh A; Soran H; Rosenblit P; O'Dea L; Stevenson M
Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):537-546. PubMed ID: 29889589
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.
Spagnuolo CM; Hegele RA
Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
